<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125247">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472016</url>
  </required_header>
  <id_info>
    <org_study_id>M12-375</org_study_id>
    <nct_id>NCT01472016</nct_id>
  </id_info>
  <brief_title>Study of ABT-700 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Multi-Center, Phase 1/1b, Open-Label, Dose Escalation Study of ABT-700, a Monoclonal Antibody in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and
      preliminary efficacy of ABT-700 in subjects with advanced solid tumors that may have MET
      amplification or c-Met overexpression. ABT-700, previously known as h224G11 in publications,
      is an anti-c-Met antibody. The early clinical development plan for ABT-700 is based on the
      activity demonstrated in preclinical models. Up to 124 subjects will be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of ABT-700 when administered as monotherapy and in combination with docetaxel or 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinib</measure>
    <time_frame>First cycle of treatment through 60 day follow-up visit</time_frame>
    <description>Evaluation of vital signs, clinical lab testing, physical exams and adverse event monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To Evaluate the pharmacokinetics of ABT-700 when administered as monotherapy and in combination with docetaxel or 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinib</measure>
    <time_frame>At each cycle of treatment through 60 days after last dose.</time_frame>
    <description>Pharmacokinetic profile of ABT-700 analyzed from blood samples</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the recommended Phase 2 dose for ABT-700</measure>
    <time_frame>First cycle of treatment through 60 day follow-up visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the preliminary efficacy of ABT-700 when administered as monotherapy and in combination with docetaxel or 5-fluoruracil, folinic acid, irinotecan and cetuximab (FOLFIRI/cetuximab) or erlotinib</measure>
    <time_frame>Screening through 60 day follow-up visit</time_frame>
    <description>Objective response rate (complete and partial response), progression-free survival and duration of response</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-700 will be administered by intravenous infusion at escalating dose levels in 21-day dosing cycles. Additional subjects will be enrolled in an expansion cohort that will further evaluate ABT-700.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-700 plus docetaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-700 plus FOLFIRI/cetuximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABT-700 plus erlotinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-700</intervention_name>
    <description>ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles.</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.</description>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Cetuximab will be administered by intravenous infusion weekly.</description>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib</intervention_name>
    <description>Erlotinib will be taken orally daily.</description>
    <arm_group_label>Cohort D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-700</intervention_name>
    <description>ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.</description>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject with advanced solid tumors; Dose-expansion: evidence for MET gene
             amplification.

          -  Subject must have disease: a) that is not amenable to surgical resection, or b) that
             has progressed or recurred despite standard therapy, or c) that has failed to respond
             to standard therapy, or d) for which no effective therapy exists.

          -  Subject cannot tolerate or must not be eligible for other approved therapeutic
             options with known survival advantage.

          -  Subjects enrolled on the combination therapy phase must satisfy the above inclusion
             criteria and also the following: Subjects must have inoperable, locally advanced or
             metastatic cancer and be eligible to receive docetaxel or FOLFIRI/cetuximab or
             erlotinib in combination with ABT-700.

        Exclusion Criteria:

          -  Subject has received anticancer therapy including chemotherapy, immunotherapy,
             radiation therapy, immunotherapy, biologic, or any investigational therapy within a
             period of 21 days, or herbal therapy within 7 days prior to the first dose of
             ABT-700.

          -  Subjects with uncontrolled metastases of the central nervous system. Subjects with
             brain metastases are eligible provided they have shown clinical and radiographic
             stable disease after definitive therapy and have not used steroids for at least 1
             month prior to first dose of ABT-700.

          -  Subject has unresolved adverse events &gt; Grade 1 from prior anticancer therapy except
             for alopecia or anemia.

          -  Subject has had major surgery within 21 days prior to the first dose of ABT-700.

          -  Subjects enrolled on the combination therapy phase must not meet the above exclusion
             criteria and must be eligible to receive docetaxel or FOLFIRI/cetuximab or erlotinib
             per most current prescribing information, or at the discretion of the Investigator.
             Subjects with K-Ras mutation-positive colorectal cancer will be excluded from
             receiving FOLFIRI/cetuximab.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louie Naumovski, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 64046</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 66110</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 57555</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 66111</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 103795</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75774</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 124257</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 124396</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 123755</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 82302</name>
      <address>
        <city>Tainan, ROC</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 75773</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 5, 2017</lastchanged_date>
  <firstreceived_date>October 14, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>c-Met overexpression</keyword>
  <keyword>MET amplification</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>h224G11</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
